1088991-73-4
1088991-73-4 structure
- Name: Filorexant
- Chemical Name: [(2R,5R)-5-[(5-fluoropyridin-2-yl)oxymethyl]-2-methylpiperidin-1-yl]-(5-methyl-2-pyrimidin-2-ylphenyl)methanone
- CAS Number: 1088991-73-4
- Molecular Formula: C24H25FN4O2
- Molecular Weight: 420.479
- Catalog: Signaling Pathways GPCR/G Protein Orexin Receptor (OX Receptor)
- Create Date: 2017-10-17 18:55:47
- Modify Date: 2025-08-26 17:07:29
-
Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).
| Name | [(2R,5R)-5-[(5-fluoropyridin-2-yl)oxymethyl]-2-methylpiperidin-1-yl]-(5-methyl-2-pyrimidin-2-ylphenyl)methanone |
|---|---|
| Synonyms |
Filorexant
[(2R,5R)-5-{[(5-Fluoro-2-pyridinyl)oxy]methyl}-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]methanone Filorexant [USAN] UNII-E6BTT8VA5Z MK-6096 ((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone Methanone, [(2R,5R)-5-[[(5-fluoro-2-pyridinyl)oxy]methyl]-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]- 2-{2-[((2R,5R)-5-{[(5-fluoro-2-pyridinyl)oxy]methyl}-2-methyl-1-piperidinyl)carbonyl]-4-methylphenyl}pyrimidine 2-(2-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)carbonyl)-4-methylphenyl)-pyrimidine |
| Description | Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding). |
|---|---|
| Related Catalog | |
| Target |
Ki: < 3 nM(Orexin receptor)[1]. |
| In Vitro | In radioligand binding and functional cell based assays Filorexant (MK-6096) demonstrated potent binding and antagonism of both human OX(1)R and OX(2)R (<3 nM in binding, 11 nM in FLIPR), with no significant off-target activities against a panel of >170 receptors and enzymes. Filorexant (MK-6096) occupies 90% of human OX(2)Rs expressed in transgenic rats at a plasma concentration of 142 nM. |
| In Vivo | Filorexant (MK-6096) dose-dependently reduced locomotor activity and significantly increased sleep in rats (3-30 mg/kg) and dogs (0.25 and 0.5 mg/kg). |
| Animal Admin | Animal administration[1] The male Sprague Dawley rats (n = 8/study; age: 3-6 months; weight: 450-600 g) were singly housed with water and food ad libitum and a 12 h light: 12 h dark cycle with lights on at 04:00 and off at 16:00. Sleep studies were conducted to evaluate Filorexant (3 and 10 mg/kg, p.o.), DORA-22 (10 mg/kg, p.o.) and almorexant (3 and 30 mg/kg, p.o.), employing a counterbalanced crossover design in which all animals were alternatively treated with drug and vehicle daily for either 3 or 7 consecutive days (for DORA-22 and Filorexant, respectively): 2 baseline days (no dosing), a 2 day vehicle-only run-in, a 3 or 7-day arm of drug or vehicle followed by 3 or 7 days of conditional crossover. Effects of compound treatments relative to vehicle (20% Vitamin E TPGS, p.o.) were evaluated following administration in the active phase). |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 540.2±50.0 °C at 760 mmHg |
| Molecular Formula | C24H25FN4O2 |
| Molecular Weight | 420.479 |
| Flash Point | 280.5±30.1 °C |
| Exact Mass | 420.196167 |
| PSA | 68.21000 |
| LogP | 2.77 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.576 |
| Precursor 9 | |
|---|---|
| DownStream 0 | |
![[(3R,6R)-6-methylpiperidin-3-yl]methanol structure](https://image.chemsrc.com/caspic/357/1088994-09-5.png)
